Border to Coast Pensions Partnership Ltd Acquires 30,245 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Border to Coast raised its stake in Thermo Fisher by 17.8% in Q4, acquiring 30,245 shares to hold 200,442 shares (about $116.36M), making the stock its 9th-largest holding and ~2.0% of the portfolio.
• Q4 results beat expectations: Thermo Fisher reported $6.57 EPS vs. $6.45 expected and revenue of $12.22 billion, up 7.2% year-over-year.
• Dividend up; insider selling noted: the company increased its quarterly dividend from $0.43 to $0.47 (annualized $1.88, yield ~0.4%), while CEO Marc N. Casper sold 5,000 shares for roughly $2.56 million.

Border to Coast Pensions Partnership Ltd boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 17.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 200,442 shares of the medical research company's stock after acquiring an additional 30,245 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Border to Coast Pensions Partnership Ltd's portfolio, making the stock its 9th biggest holding. Border to Coast Pensions Partnership Ltd owned 0.05% of Thermo Fisher Scientific worth $116,358,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth about $29,000. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $28,000. Highline Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after buying an additional 33 shares during the last quarter. Finally, Cloud Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $31,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.8%

Shares of TMO stock opened at $531.69 on Thursday. The company's 50-day moving average price is $502.46 and its 200-day moving average price is $550.12. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The stock has a market cap of $197.59 billion, a price-to-earnings ratio of 29.97, a PEG ratio of 2.82 and a beta of 0.97. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating analysts' consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $12.22 billion for the quarter, compared to analysts' expectations of $11.95 billion. During the same period in the prior year, the firm posted $6.10 earnings per share. The firm's quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's payout ratio is currently 10.60%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. TD Cowen lowered their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research note on Friday, January 30th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a research note on Tuesday. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Finally, UBS Group restated a "neutral" rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $631.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.